Home Healthcare Ovarian Cancer Market
ovarian cancer market

Ovarian Cancer Market Share, Size, Trends, Industry Analysis Report, By Type (Epithelial Tumors, Germ Cell Tumors, Stromal Tumors, and Primary Peritoneal Cancer); By Diagnosis; By Therapeutic Treatment; By End-User; By Region; Segment Forecast, 2022 - 2030

  • Published Date: Oct 2022
  • Pages: 118
  • Format: PDF
  • Report ID: PM1369
  • Base Year: 2021
  • Historical Data: 2018-2020

Report Summary

The global Ovarian Cancer market was valued at USD 1.57 billion in 2021 and is expected to grow at a CAGR of 23.7% during the forecast period. The worldwide market is also anticipated to expand throughout the forecast period due to increased healthcare awareness amongst the population, innovations in medication to treat ovarian cancer, and higher government support are projected to drive the worldwide ovarian cancer market. In addition, a rise in product approval is a key factor in propelling the overall market.

Ovarian Cancer Market Size
Know more about this report: Request for sample pages

One of the most terrible types of cancer that affect many women is ovarian cancer. The ovaries in this malignancy encounter aberrant cell proliferation, which can infiltrate or negatively impact other bodily organs like the liver, lymph nodes, intestine and bladder linings, abdominal layers, and lymph nodes. The early stages of this cancer are accompanied by a few nebulous symptoms that become more obvious as the malignancy progresses. These signs include bloating, pelvic pain, belly swelling, and appetite loss.

The most deadly gynecologic malignancy and the fifth most common incidence of cancer-related fatalities in women in the United States is ovarian cancer (OC). In its first prediction, the American Cancer Society (ACS) predicted that 13,940 women would pass away from the disease in the United States alone in 2020, and 21,750 women would be diagnosed with OC. However, given the negative effects of COVID-19 on human life and the efficiency of healthcare facilities, these preliminary forecasts could change.

Unprecedented difficulties are affecting the oncology sector as the world deals with the coronavirus disease 2019 crisis. Ovarian cancer (OC) patients have been impacted by a delay in diagnosis, surgery, chemotherapy, and radiation treatments, as well as oncology follow-ups being carried out via telemedicine rather than in-person visits at this tough time. The concerns with COVID-19 and cancer treatment are being weighed against the effects of delayed cancer treatment by OC patients and their physicians. Higher levels of cancer anxiety, despair, and depressive symptoms have been linked to the delay in medical care that OC women are facing.

Industry Dynamics

Growth Drivers
The risk of developing ovarian cancer is higher in women who have ovulated more frequently throughout their lifetime, including females who have not given birth and those who started ovulating at an early age. This cancer is a relatively uncommon form of cancer compared to others. According to the American Cancer Society, inherited genetic risk contributes to about 10% of occurrences of ovarian cancer.

According to the American Cancer Society, ovarian cancer cases in the country are expected to rise in 2022. About 12,810 women will pass away from ovarian cancer, while approximately 19,880 women will acquire a new diagnosis of the disease. The sixth most common cancer among women, ovarian cancer kills more people than any other malignancy of the female reproductive system. About 1 in 78 women may develop this type of cancer. Older women seem to develop this malignancy the most. Ovarian cancer is discovered in almost half of women aged 63 or older. African American women are less likely to experience it than white women. Therefore, the rising prevalence of cancer has led to an increase in the demand for treatment which is driving the market growth over the forecast period.

Report Segmentation

The market is primarily segmented based on type, diagnosis, therapeutic treatment, end-user, and region.

By Type

By Diagnosis

By Therapeutic Treatment

By End-User

By Region

  • Epithelial Tumors
  • Germ Cell Tumors
  • Stromal Tumors
  • Primary Peritoneal Cancer
  • Computed Tomography (C.T.) Scans
  • Ultrasound
  • Barium Enema X-Ray
  • Magnetic Resonance Imaging (MRI) Scans
  • Chest X-Ray
  • Positron Emission Tomography (PET) Scan
  • Other Diagnostic Tests
  • Chemotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Hormone Therapy
  • Other Therapeutic Treatments
  • Surgery
  • Hospitals
  • Diagnostic Centers
  • Drug Stores
  • Online Pharmacies
  • Other End Users
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Know more about this report: Request for sample pages

Imaging techniques industry is expected to witness the fastest growth

The biggest portion was accounted for by imaging techniques since early detection and cancer staging is becoming more and more crucial. The initial imaging method to see within a tumor and gauge its size is still transvaginal ultrasonography. However, it can only be used for tiny tumors. CT scan is favored for cancer staging. To determine the extent of the disease and detect metastases, more sophisticated imaging methods, including MRI and PET scans, are performed.

Throughout the projected period, the market for blood tests is anticipated to expand steadily because of technical improvements and rising consumer awareness. Elevated levels of several biomarkers, which function as tumor indicators and aid in the diagnosis, can be caused by ovarian cancer.

The epithelial tumors segment industry accounted for the highest market share in 2021

The most prevalent type of ovarian cancer, epithelial cancer, starts in the tissue that surrounds the ovaries. It comprises primary ovarian cancer and fallopian tube cancer. The most frequent type of this cancer is high-grade serous (HGSOC), which often spreads before being discovered. Ovarian cancer tumors are removed during debulking surgery. Serous, mucinous, endometrioid, or clear cell epithelial cancers are also possible. Epithelial cell carcinoma is typically only discovered in patients after cancer has spread to the peritoneal cavity. Patients are typically detected in an advanced stage, drastically reducing the number of available treatments and the likelihood of survival.

Stromal and germ cell cancers account for a lesser portion of this market. The tissues that make hormones like testosterone, progesterone, and estrogen become stromal tumors. Although uncommon, germ cell tumors are most common in women between 20 and 30. The second most frequent malignancy to impact the female reproductive system is ovarian cancer (gynecological cancer). The most frequent type of cancer is the uterus (endometrial). A woman's lifetime risk of developing ovarian cancer is 1 in 78. More than 21,400 patients received an ovarian cancer diagnosis in 2021. Nine out of ten of these instances are epithelial ovarian cancer. People over 65 are affected by more than half of epithelial ovarian cancer occurrences.

Hospital is expected to hold the significant revenue share

The rise in cancer diagnoses in hospitals, increased consumer awareness, and rising investments in healthcare infrastructure in developing and undeveloped nations are all factors contributing to the growth of this market. As cancer research funding increases globally, the market for research institutes is anticipated to expand faster throughout the forecast period.

The demand in North America  is expected to witness significant growth

Due to the U.S.'s outstanding commercial success in gynecologic diagnostics, North America accounted for the highest proportion. Other factors boosting the market in this region include favorable government initiatives, an increase in healthcare spending, and the presence of important manufacturers. It is projected that the United States will control a significant portion of the North American market. The rising elderly population, more awareness, and the presence of significant players are the main drivers of the demand for ovarian cancer diagnostics in the United States. The market’s growth in the United States is also greatly influenced by technological developments and rising government-supported research investment.

Further, due to rapid development in emerging economies, improved healthcare infrastructure, rising disposable income, and increased consumer awareness, Asia Pacific is anticipated to grow fastest throughout the projection period. Developing nations like China, India, and South Korea are anticipated to substantially expand the ovarian cancer diagnostics market during the forecast period. Although there has been a little decline in instances across the country over the previous ten years, as the elderly population grows, it is projected that cases will increase. The government has implemented control measures to reduce mortality and is funding research to advance ovarian cancer detection.

Competitive Insight

Some of the major players operating in the global market include AstraZeneca Inc., Aetera Zenteris Inc., Bristol-Myers Squibb Corp., Boehringer Ingelheim GmbH, Eli Lilly and Company, GlaxoSmithKline plc, Genentech Inc., Johnson & Johnson Corp., Janssen Pharmaceuticals, Inc., Novogen, Inc., Oasmia Pharmaceutical Inc, Pfizer Inc., Roche Ltd., and Tesaro Inc.

Recent Developments

In May 2021, BDPARIB (RUCAPARIB) was introduced by BDR Pharmaceutical to treat progressive prostate, ovarian, and other malignancies. BDPARIB is the first affordable generic medicine in India that is available as a tablet, and its cost of treatment is lower than that of any other drugs now on the market.

In November 2021, the SORAYA trial, which is being conducted by ImmunoGen Inc., will examine the security and effectiveness of mirvetuximab soravtansine (mirvetuximab) monotherapy in individuals with folate receptor alpha (FR)-high metal ovarian cancer who've already previously had Avastin therapy (bevacizumab).

Ovarian Cancer Market Report Scope

Report Attributes


Market size value in 2022

USD 1.77 billion

Revenue forecast in 2030

USD 9.67 billion


23.7% from 2022 - 2030

Base year


Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD billion and CAGR from 2022 to 2030

Segments Covered

By Type, By Diagnosis, By Therapeutic Treatment, By End-User, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key Companies

AstraZeneca Inc., Aetera Zenteris Inc., Bristol-Myers Squibb Corp., Boehringer Ingelheim GmbH, Eli Lilly and Company, GlaxoSmithKline plc, Genentech Inc., Johnson & Johnson Corp., Janssen Pharmaceuticals, Inc., Novogen, Inc., Oasmia Pharmaceutical Inc, Pfizer Inc., Roche Ltd., and Tesaro Inc.

Key Take-Away
Polaris Market Research
Ovarian Cancer Market Size Global Report, 2022 - 2030